Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NF&#954;B Activity and Breast Cancer Stem Cells

Irida Kastrati; Loruhama Delgado-Rivera; Gergana Georgieva; Gregory R. J. Thatcher; Jonna Frasor

doi:10.3791/54798

Synthèse et caractérisation d'un promédicament Aspirin-fumarate qui inhibe l'activité de ...

JoVE Journal
Cancer Research

A subscription to JoVE is required to view this content. Sign in or start your free trial.

JoVE Journal Cancer Research

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Synthèse et caractérisation d'un promédicament Aspirin-fumarate qui inhibe l'activité de NFkB et du sein des cellules souches du cancer

Full Text

12,739 Views

13:38 min

January 18, 2017

DOI: 10.3791/54798-v

Irida Kastrati¹, Loruhama Delgado-Rivera², Gergana Georgieva³, Gregory R. J. Thatcher², Jonna Frasor¹

¹Physiology and Biophysics, College of Medicine,University of Illinois at Chicago, ²Medicinal Chemistry and Pharmacognosy, College of Medicine,University of Illinois at Chicago, ³College of Pharmacy,University of Illinois at Chicago

Please note that some of the translations on this page are AI generated. Click here for the English version.

Overview

This procedure demonstrates the synthesis and characterization of the anti-inflammatory aspirin-fumarate prodrug GTCpFE, which enhances anti-NFkappaB and anti-cancer stem cell activity in breast cancer cells. This method aims to repurpose anti-inflammatory drugs for targeting therapy-resistant breast cancer stem cells.

Key Study Components

Area of Science

Cancer therapeutics
Pharmacology
Drug repurposing

Background

Aspirin-fumarate prodrug GTCpFE is designed to improve therapeutic outcomes.
Resistance in breast cancer stem cells poses a significant challenge in treatment.
Multidisciplinary approaches enhance drug development and characterization.
Understanding anti-inflammatory mechanisms can lead to novel cancer therapies.

Purpose of Study

To synthesize the aspirin-fumarate prodrug GTCpFE.
To evaluate its anti-NFkappaB activity in breast cancer cells.
To assess its potential against cancer stem cells.

Methods Used

Synthesis of GTCpFE using methanol and water in a round-bottom flask.
Characterization of anti-NFkappaB activity in breast cancer cells.
Collaboration between graduate and pharmacy students for experimental execution.
Utilization of a plastic plunger syringe for precise measurements.

Main Results

Successful synthesis of the aspirin-fumarate prodrug GTCpFE.
Demonstrated enhanced anti-NFkappaB activity in treated breast cancer cells.
Potential for repurposing anti-inflammatory drugs in cancer therapy.
Characterization results support further investigation into GTCpFE.

Conclusions

The aspirin-fumarate prodrug GTCpFE shows promise in targeting resistant cancer stem cells.
Multidisciplinary approaches are effective in drug development.
Further studies are warranted to explore therapeutic applications.

Frequently Asked Questions

What is the significance of GTCpFE?

GTCpFE is significant for its potential to improve anti-cancer therapies targeting resistant breast cancer stem cells.

How does GTCpFE work?

GTCpFE enhances anti-NFkappaB activity, which may help in overcoming resistance in cancer treatments.

Who conducted the study?

The study was conducted by graduate and pharmacy students under the supervision of Dr. Gregory Thatcher and Dr. Jonna Frasor.

What methods were used in the synthesis?

The synthesis involved mixing methanol and water in a round-bottom flask using precise measurements.

What are the future implications of this research?

Future implications include potential advancements in cancer therapeutics through drug repurposing and enhanced treatment strategies.

Cette procédure démontrera comment nous avons synthétisé et caractérisé l’activité des cellules souches anti-NFκB et anticancéreuses d’un promédicament à base d’aspirine-fumarate.

Les objectifs généraux de cette procédure sont de démontrer comment le promédicament anti-inflammatoire aspirine-fumarate GTCpFE est synthétisé et comment il améliore l’activité des cellules souches anti-NFkappaB et anticancéreuses dans les cellules cancéreuses du sein. Cette méthode peut aider à répondre à des questions clés dans le domaine des thérapies anticancéreuses en montrant comment nous pouvons réutiliser ou même améliorer les médicaments anti-inflammatoires pour cibler les cellules souches du cancer du sein résistantes au traitement. Le principal avantage de cette technique est que nous utilisons l’approche multidisciplinaire pour obtenir et caractériser le promédicament amélioré aspirine-fumarate.

Loruhama Delgado-Rivera, une étudiante diplômée du laboratoire du Dr Gregory Thatcher, fera la démonstration de la synthèse du promédicament aspirine-fumarate GTCpFE. Tandis que l’activité anti-NFkappaB de GTCpFE dans les cellules cancéreuses du sein sera démontrée par Gergana Georgieva, étudiante chercheuse en pharmacie dans le laboratoire de la Dre Jonna Frasor. À l’aide d’une seringue à piston en plastique, mesurez 0,81 millilitre de méthanol et mélangez-le dans 10 millilitres d’eau dans une fiole à fond rond.

View the full transcript and gain access to thousands of scientific videos

Explore More Videos

Recherche Issue 119 une inflammation un promédicament l'aspirine le fumarate le facteur ĸB nucléaire des cellules souches le cancer du sein le cancer